Despite high initial response rates, a subset of dogs with B-cell lymphoma responds less robustly to CHOP-based chemotherapy and experiences shorter survival. One hundred and four dogs with nodal B-cell lymphoma were treated with a response-based CHOP (RBCHOP) protocol modified based on response to individual drugs during the first chemotherapy cycle. Dogs achieving complete (CR) or partial response (PR) at week 3, following treatment with vincristine and cyclophosphamide, received RBCHOP 1 (n = 72), a protocol sequentially rotating vincristine, cyclophosphamide, and doxorubicin. Dogs without a detectable response at week 3 that subsequently achieved CR or PR following treatment with doxorubicin received RBCHOP 2 (n = 14), in which four doses of doxorubicin were given consecutively followed by vincristine and cyclophosphamide. Dogs that failed to respond at week 3 and then to doxorubicin at week 5 assessment were offered rescue chemotherapy (RBCHOP 3, n = 18). Median progression free survival (PFS) and overall survival time (OST) were similar between RBCHOP 1 (PFS 210 days, OST 354 days) and RBCHOP 2 (PFS 220 days, OST 456 days), but significantly shorter for RBCHOP 3 (PFS 34 days, OST 80.5 days, P < 0.001). No presenting signalment nor hematologic variable differentiated patient cohort, however, dogs in RBCHOP 2 and RBCHOP 3 were more likely to have a lymphocytosis at diagnosis (P = 0.02 and 0.04, respectively). Protocol modification based on response during the first cycle resulted in similar toxicity profiles and outcomes to previously published variants of CHOP, and prognosis remained poor for dogs failing to respond during the first treatment cycle.

中文翻译：

---

犬 B 细胞淋巴瘤 CHOP 化疗的基于反应的改良

尽管初始反应率很高，但一部分患有 B 细胞淋巴瘤的狗对基于 CHOP 的化疗反应较弱，并且生存期较短。104 只患有淋巴结 B 细胞淋巴瘤的狗接受了基于反应的 CHOP (RBCHOP) 方案的治疗，该方案基于第一个化疗周期期间对单个药物的反应进行了修改。在用长春新碱和环磷酰胺治疗后的第 3 周达到完全 (CR) 或部分反应 (PR) 的狗接受了 RBCHOP 1 (n = 72)，这是一种顺序轮换长春新碱、环磷酰胺和多柔比星的方案。在第 3 周没有可检测到的反应，随后在多柔比星治疗后达到 CR 或 PR 的狗接受 RBCHOP 2（n = 14），其中连续给予四剂多柔比星，然后是长春新碱和环磷酰胺。在第 3 周没有反应，然后在第 5 周评估时对多柔比星没有反应的狗被提供抢救化疗（RBCHOP 3，n = 18）。RBCHOP 1（PFS 210 天，OST 354 天）和 RBCHOP 2（PFS 220 天，OST 456 天）的中位无进展生存期 (PFS) 和总生存期 (OST) 相似，但 RBCHOP 3 (PFS 34) 显着缩短天，OST 80.5 天，P  < 0.001)。没有呈现信号或血液学变量区分患者队列，然而，RBCHOP 2 和 RBCHOP 3 的狗在诊断时更可能有淋巴细胞增多症（分别为P  = 0.02 和 0.04）。基于第一个周期期间的反应修改方案导致与先前发表的 CHOP 变体相似的毒性特征和结果，并且对于在第一个治疗周期中未能反应的狗的预后仍然很差。